MERONEM

Meronem Adverse Events Reported to the FDA Over Time

How are Meronem adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Meronem, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Meronem is flagged as the suspect drug causing the adverse event.

Most Common Meronem Adverse Events Reported to the FDA

What are the most common Meronem adverse events reported to the FDA?

Toxic Epidermal Necrolysis	22 (3.36%)
Multi-organ Failure	21 (3.21%)
Drug Interaction	20 (3.05%)
Cholestasis	18 (2.75%)
Sepsis	18 (2.75%)
Poor Quality Drug Administered	16 (2.44%)
Pyrexia	13 (1.98%)
Thrombocytopenia	13 (1.98%)
Convulsion	11 (1.68%)
Tremor	11 (1.68%)
Alanine Aminotransferase Increased	10 (1.53%)
	Show More
Death	10 (1.53%)
Epilepsy	10 (1.53%)
Pneumonia	10 (1.53%)
Hepatic Failure	9 (1.37%)
Paraesthesia	9 (1.37%)
Pancytopenia	8 (1.22%)
Rash Maculo-papular	8 (1.22%)
Stevens-johnson Syndrome	8 (1.22%)
Aspartate Aminotransferase Increase...	7 (1.07%)
Cerebral Haemorrhage	7 (1.07%)
Cholangitis	7 (1.07%)
Hypotension	7 (1.07%)
Nausea	7 (1.07%)
Pain In Extremity	7 (1.07%)
Rash	7 (1.07%)
Anticonvulsant Drug Level Decreased	6 (.92%)
Gastrointestinal Haemorrhage	6 (.92%)
Pruritus	6 (.92%)
Rash Macular	6 (.92%)
Renal Failure	6 (.92%)
Agranulocytosis	5 (.76%)
Anaphylactic Reaction	5 (.76%)
Arthralgia	5 (.76%)
Bone Marrow Failure	5 (.76%)
Drug Hypersensitivity	5 (.76%)
Dysgeusia	5 (.76%)
Gamma-glutamyltransferase Increased	5 (.76%)
Hepatitis	5 (.76%)
Hepatotoxicity	5 (.76%)
Transaminases Increased	5 (.76%)
Vanishing Bile Duct Syndrome	5 (.76%)
Blood Alkaline Phosphatase Increase...	4 (.61%)
Blood Creatine Phosphokinase Increa...	4 (.61%)
Blood Lactate Dehydrogenase Increas...	4 (.61%)
Grand Mal Convulsion	4 (.61%)
Hyperbilirubinaemia	4 (.61%)
International Normalised Ratio Incr...	4 (.61%)
Partial Seizures	4 (.61%)
Prothrombin Time Prolonged	4 (.61%)
Acute Respiratory Distress Syndrome	3 (.46%)
Anticonvulsant Drug Level Below The...	3 (.46%)
Disseminated Intravascular Coagulat...	3 (.46%)
Drug Effect Decreased	3 (.46%)
Dry Mouth	3 (.46%)
Intravascular Haemolysis	3 (.46%)
Leukopenia	3 (.46%)
Liver Disorder	3 (.46%)
Loss Of Consciousness	3 (.46%)
Oedema	3 (.46%)
Renal Failure Acute	3 (.46%)
Respiratory Failure	3 (.46%)
Status Epilepticus	3 (.46%)
Altered State Of Consciousness	2 (.31%)
Anosmia	2 (.31%)
Aplasia Pure Red Cell	2 (.31%)
Apolipoprotein Increased	2 (.31%)
Arrhythmia	2 (.31%)
Bronchospasm	2 (.31%)
Cellulitis	2 (.31%)
Chest Discomfort	2 (.31%)
Cholelithiasis	2 (.31%)
Condition Aggravated	2 (.31%)
Dialysis	2 (.31%)
Diarrhoea	2 (.31%)
Drug Ineffective	2 (.31%)
Dyskinesia	2 (.31%)
Dyspnoea	2 (.31%)
Encephalopathy	2 (.31%)
Enuresis	2 (.31%)
Eosinophilia	2 (.31%)
General Physical Health Deteriorati...	2 (.31%)
Hepatitis Cholestatic	2 (.31%)
Hepatitis Toxic	2 (.31%)
Hypernatraemia	2 (.31%)
Hypersensitivity	2 (.31%)
Hypokalaemia	2 (.31%)
Jaundice	2 (.31%)
Lung Infection	2 (.31%)
Malaise	2 (.31%)
Myoclonus	2 (.31%)
Oedema Peripheral	2 (.31%)
Postpartum Sepsis	2 (.31%)
Prothrombin Level Decreased	2 (.31%)
Prothrombin Time Shortened	2 (.31%)
Refusal Of Treatment By Patient	2 (.31%)
Septic Embolus	2 (.31%)
Septic Shock	2 (.31%)
Sleep Disorder	2 (.31%)
Spondylitis	2 (.31%)
Superinfection	2 (.31%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Meronem, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Meronem is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Meronem

What are the most common Meronem adverse events reported to the FDA?

Epidermal And Dermal Conditions	69 (10.53%)
Hepatic And Hepatobiliary	53 (8.09%)
Infections - Pathogen Unspecified	46 (7.02%)
Seizures	33 (5.04%)
Hepatobiliary	29 (4.43%)
Therapeutic And Nontherapeutic Effe...	28 (4.27%)
Neurological	25 (3.82%)
Medication Errors	19 (2.9%)
Anemias Nonhemolytic And Marrow Dep...	16 (2.44%)
Hematology Investigations	16 (2.44%)
Movement Disorders	14 (2.14%)
	Show More
Allergic Conditions	13 (1.98%)
Body Temperature Conditions	13 (1.98%)
Platelet	13 (1.98%)
Bile Duct	12 (1.83%)
Enzyme	12 (1.83%)
Respiratory	11 (1.68%)
Decreased And Nonspecific Blood Pre...	10 (1.53%)
Fatal Outcomes	10 (1.53%)
White Blood Cell	10 (1.53%)
Renal Disorders	9 (1.37%)
Toxicology And Therapeutic Drug Mon...	9 (1.37%)
Bacterial Infectious	8 (1.22%)
Central Nervous System Vascular	8 (1.22%)
Gastrointestinal Signs	8 (1.22%)
Joint	7 (1.07%)
Musculoskeletal And Connective Tiss...	7 (1.07%)
Gastrointestinal Hemorrhages	6 (.92%)
Electrolyte And Fluid Balance Condi...	5 (.76%)
Fungal Infectious	5 (.76%)
Coagulopathies And Bleeding Diathes...	4 (.61%)
Hemolyses And Related Conditions	4 (.61%)
Lower Respiratory Tract Disorders	4 (.61%)
Cardiac Arrhythmias	3 (.46%)
Gallbladder	3 (.46%)
Gastrointestinal Motility And Defec...	3 (.46%)
Salivary Gland Conditions	3 (.46%)
Urinary Tract Signs	3 (.46%)
Arteriosclerosis, Stenosis, Vascula...	2 (.31%)
Bronchial Disorders	2 (.31%)
Cranial Nerve Disorders	2 (.31%)
Encephalopathies	2 (.31%)
Genitourinary Tract	2 (.31%)
Hematological And Lymphoid Tissue T...	2 (.31%)
Lifestyle Issues	2 (.31%)
Lipid Analyses	2 (.31%)
Microbiology And Serology	2 (.31%)
Sleep Disorders	2 (.31%)
Vascular	2 (.31%)
Vascular Inflammations	2 (.31%)
Acid-base	1 (.15%)
Adrenal Gland	1 (.15%)
Ancillary Infectious Topics	1 (.15%)
Angiedema And Urticaria	1 (.15%)
Anxiety Disorders	1 (.15%)
Appetite And General Nutritional	1 (.15%)
Bladder And Bladder Neck Disorders	1 (.15%)
Cardiac Therapeutic Procedures	1 (.15%)
Cardiac Valve	1 (.15%)
Congenital And Hereditary	1 (.15%)
Coronary Artery	1 (.15%)
Deliria	1 (.15%)
Embolism And Thrombosis	1 (.15%)
Endocrine Neoplasms Benign	1 (.15%)
Eye	1 (.15%)
Gastrointestinal Conditions	1 (.15%)
Gastrointestinal Inflammatory Condi...	1 (.15%)
Gastrointestinal Ulceration And Per...	1 (.15%)
Hearing	1 (.15%)
Hematopoietic Neoplasms	1 (.15%)
Hepatobiliary Therapeutic Procedure...	1 (.15%)
Immune	1 (.15%)
Leukemias	1 (.15%)
Metastases	1 (.15%)
Muscle	1 (.15%)
Nephropathies	1 (.15%)
Neurological Disorders Of The Eye	1 (.15%)
Ocular Infections, Irritations And ...	1 (.15%)
Oral Soft Tissue Conditions	1 (.15%)
Peripheral Neuropathies	1 (.15%)
Procedural And Device Related Injur...	1 (.15%)
Renal And Urinary Tract Investigati...	1 (.15%)
Skin Vascular Abnormalities	1 (.15%)
Soft Tissue Neoplasms Benign	1 (.15%)
Spleen, Lymphatic And Reticulendoth...	1 (.15%)
Tissue	1 (.15%)
Upper Respiratory Tract Disorders	1 (.15%)
Vascular Hemorrhagic	1 (.15%)
Vascular Hypertensive	1 (.15%)
Viral Infectious	1 (.15%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Meronem, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Meronem is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.